top of page

Investigating the efficacy, safety, and tolerability of ML-004 in autistic adolescents 

We are working with Maplight and other sites around Australia, Canada, and the United States, to investigate the safety, tolerability, and efficacy of a pharmaceutical therapy called ML-004.

​

We are looking to find out whether ML-004
might address the characteristics of autism that can make social interaction challenging.

Recruitment

To be eligible, participants must be:

  • Be aged 12-17 years old 

  • Have an autism diagnosis

  • Have a relative, housemate, friend, or other study partner to assist during the study and attend clinic visits

​

There are additional requirements for participation. The study staff will explain the complete list of requirements.

​

This study is currently OPEN. Register your interest below. â€‹

Contact CAN Research

Brain and Mind Centre

University of Sydney

94 Mallet Street

Camperdown, NSW, 2050

Tel: 02 9114 4104

Final_CAN_logo_2022 (1).png

The Children’s Hospital at Westmead

Cnr Hawkesbury Road & Hainsworth Street

Westmead, NSW, 2145

​

We use identity-first language (autistic person)  rather than person-first language (person with autism) throughout the site.
Find out more about our decision to do so. 

 

Privacy Policy

bottom of page